Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.
**THE CORE CONCERN**
The Beneish M-Score of 1.33 breaches the −1.78 manipulation threshold on a scale where values closer to zero are more indicative of potential earnings manipulation. The model assigned comparable readings to Enron in FY1997–1998. This reading is driven primarily by the SGI component of 6.50, reflecting 550% year-on-year revenue growth. Revenue remains negligible in absolute terms—reported as $0.0B across the five-year window—yet registers an 11.3% CAGR over four years. The Altman Z-Score of 1.31 places the company inside the distress zone (<1.81), while short interest stands at 30.6% of float and beta at 4.04. Accruals (NI−OCF)/Assets equal 0.000 and there is no cumulative NI–OCF divergence, so the quantitative concern centers on the M-Score and Z-Score combination rather than cash-flow quality.
**HISTORICAL PRECEDENT**
The M-Score pattern most closely tracks pre-collapse Enron, where the same model produced readings above −1.78 three years before the 2001 bankruptcy. In that case, rapid reported growth metrics masked underlying revenue recognition issues. Biotechnology development-stage companies have produced analogous statistical flags during periods of aggressive milestone or collaboration accounting, though the outcomes ranged from outright restatements to simple over-optimism about future cash inflows.
**WHAT TO VERIFY**
Three items warrant direct examination in the 10-K or 10-Q. First, the composition and timing of the revenue recognized in the year that produced the 550% increase—specifically, whether any portion is milestone-based, non-recurring, or subject to refund. Second, the breakdown of current assets and liabilities that feed the Altman Z-Score, particularly the cash runway relative to operating burn and any off-balance-sheet R&D commitments. Third, the detailed components of the Beneish SGI and DSRI indices, including the precise revenue figure used in the 550% calculation and any changes in accounts receivable or deferred revenue.
**COUNTERARGUMENTS**
High-growth dynamics can legitimately elevate several forensic ratios. A development-stage biotechnology firm with revenue expanding from a near-zero base will mechanically produce a high SGI and, by extension, an elevated M-Score even in the absence of manipulation. Clinical or collaboration revenue is often lumpy and front-loaded, which can compress the Z-Score through working-capital volatility without implying insolvency. The zero accruals ratio and absence of any NI–OCF divergence provide no supporting evidence of earnings shifting. Short interest and beta may simply reflect sector volatility and binary clinical outcomes rather than accounting concerns. These factors indicate that the flagged metrics are at least partly consistent with the economics of an early-stage biotech rather than conclusive proof of distortion.
Beneish M-Score 1.33 ❌ |
Altman Z-Score 1.31 ❌ |
Accruals Ratio 0.000 ✅ |
Short Interest 30.6% |
Beneish Score 35/35 pts |
Altman Score 20/20 pts |
Cash Div Score 0/25 pts |
Gov Score 8/20 pts |
Ticker $INBX is available to trade on eToro, where it may be available for Puts or a Short position.
Ford Motor Company develops, delivers, and services Ford trucks, sport utility vehicles, commercial vans and cars, and Lincoln luxury vehicles in the United States, Canada, the United Kingdom, Mexico, and internationally. It operates through Ford Blue, Ford Model e, Ford Pro, and Ford Credit segments. The company sells Ford and Lincoln internal combustion engine and hybrid vehicles, electric vehicles, service parts, accessories, and digital services for retail customers; develops EV and digital vehicle technologies, and software; and provides telematics and EV charging solutions. It also sells Ford and Lincoln vehicles, service parts, and accessories through distributors and dealers, as well as through dealerships to commercial fleet customers, daily rental car companies, and governments.
**THE CORE CONCERN**
Ford’s Beneish M-Score of 1.35 breaches the −1.78 manipulation threshold on a scale where proximity to zero indicates higher statistical likelihood of earnings distortion. The model assigned comparable readings to Enron in fiscal 1997–1998. This signal occurs alongside an Altman Z-Score of 0.84, firmly inside the distress zone below 1.81, and minimal insider ownership of 0.40 percent. Offsetting these readings, the accruals ratio stands at 0.000, cumulative five-year net income and operating cash flow show zero divergence, and the company has recorded no instances of positive net income paired with negative operating cash flow. Revenue has expanded steadily from $158.1 billion to $188.0 billion over four years, a 4.4 percent compound annual rate.
**HISTORICAL PRECEDENT**
The combination of an M-Score above the manipulation cutoff and a Z-Score in the distress band mirrors the profile observed at General Motors immediately prior to its 2009 bankruptcy filing. GM’s reported earnings remained positive while cash generation lagged and leverage metrics deteriorated; the eventual restructuring revealed that legacy pension and warranty obligations had been understated relative to operating realities. Ford’s current metrics do not demonstrate the same earnings-cash divergence, yet the shared pattern of elevated M-Score and sub-1.81 Z-Score warrants examination of whether similar balance-sheet pressures are present.
**WHAT TO VERIFY**
Investigators should examine three items in the most recent 10-K and 10-Q. First, the composition of the “other assets” and “other liabilities” lines that feed the Beneish DSRI and SGI variables, specifically any acceleration in deferred revenue or warranty accruals. Second, the precise inputs to the Altman Z-Score—working-capital-to-assets and retained-earnings-to-assets ratios—to determine whether the low score stems from cyclical inventory swings or from structural erosion in equity. Third, footnote disclosure on pension and OPEB discount-rate assumptions and expected return on plan assets, given that small changes in these estimates can materially affect both net income and the M-Score’s gross-margin and asset-quality components.
**COUNTERARGUMENTS**
Steady revenue growth at 4.4 percent annually can itself elevate certain Beneish inputs, particularly sales-growth and asset-quality ratios, without implying manipulation; the same dynamics have produced false-positive signals in other mature manufacturers during periods of modest expansion. The auto industry’s long cash-conversion cycles and large working-capital swings also compress the Altman Z-Score even when underlying operations remain stable. Zero cumulative earnings-cash divergence and an accruals ratio of 0.000 provide direct evidence against aggressive accrual accounting. Low insider ownership is typical for a legacy automaker with diffuse institutional ownership rather than a deliberate signal of misaligned incentives. These factors indicate that the quantitative flags may reflect industry structure and moderate growth rather than deliberate distortion.
Beneish M-Score 1.35 ❌ |
Altman Z-Score 0.84 ❌ |
Accruals Ratio 0.000 ✅ |
Short Interest 0.0% |
Beneish Score 35/35 pts |
Altman Score 20/20 pts |
Cash Div Score 0/25 pts |
Gov Score 4/20 pts |
Ticker $F is available to trade on eToro, where it may be available for Puts or a Short position.
Subscribe to Red Flags and get each new issue delivered to your inbox.
Already a member? Visit robomacro.com to log in and manage subscriptions, or use Forgot Password to set a password.
Red Flags by RoboMacro — Forensic Accounting Intelligence | Issue #34 | November 20, 2026
Models: Beneish (1999), Altman (1968). Data: Yahoo Finance, SEC EDGAR, Financial Modeling Prep.
This publication is for educational purposes only. Not investment advice. Presence of red flags does not constitute an allegation of fraud or wrongdoing. Do your own due diligence.
Cartographic Modernism